Why shoulder cartilage damage is so often missed

Shoulder pain that persists after physiotherapy, steroid injections, or a reassuring X-ray is a common and frustrating presentation. One reason it lingers without a clear explanation is that the glenohumeral joint's cartilage surfaces sit deep within the shoulder — anatomically recessed in a way that makes surface signs unreliable. Unlike the knee, where a cartilage tear often produces a distinctive locking, catching, or giving-way sensation, glenohumeral cartilage damage can cause nothing more specific than an ache at rest, pain on movement, and occasional grinding. Those same symptoms point equally to rotator-cuff pathology, subacromial impingement, or acromioclavicular joint irritation.

This overlap means clinical examination alone cannot reliably distinguish a focal cartilage defect from the more common causes of shoulder pain. A specialist can often keep several diagnoses on the table simultaneously — which is why standard imaging or a GP referral may return a result such as 'mild wear and tear' or 'no structural abnormality' when the cartilage surface itself has not been adequately assessed.

MRI is the prerequisite, not an optional extra, for identifying focal glenohumeral cartilage damage. A dedicated shoulder MRI, reviewed by a clinician with cartilage-specific experience, can reveal the grade and boundaries of a lesion — specifically whether it reaches Outerbridge Grade III (cartilage loss greater than half its depth) or Grade IV (full-thickness loss through to subchondral bone). That grading matters because it determines treatment eligibility: regenerative pathways such as ChondroFiller injection are designed for focal, well-bordered Grade III–IV defects, not for the diffuse joint-surface thinning of established glenohumeral osteoarthritis.

The distinction between a focal cartilage defect and generalised OA is not merely semantic. Focal damage, even when severe in its local area, leaves the surrounding cartilage and bone structurally intact — a prerequisite for scaffold-based regeneration. Diffuse OA does not. Getting to the right diagnosis is therefore the necessary first step before any treatment decision, restorative or otherwise, can be made.

Which patients are suitable for a ChondroFiller shoulder injection

Assuming the MRI has confirmed a focal glenohumeral lesion, four clinical factors determine whether a ChondroFiller injection is the right next step.

Defect grade and size. The lesion should reach Outerbridge Grade III or IV — significant partial or full-thickness cartilage loss across a defined area. Standard candidacy covers defects up to approximately 3 cm²; the injection route extends this to around 6 cm² for larger focal lesions, provided the lesion remains well-bordered rather than diffuse.

Intact surrounding architecture. The scaffold's mechanism depends on the defect walls. When the collagen solution gels in situ, the surrounding cartilage and subchondral bone act as a physical container, holding the forming hydrogel in place long enough for progenitor cells to migrate in. If surrounding tissue is compromised — as it is in widespread glenohumeral OA — there is no stable perimeter for the scaffold to occupy, and the procedure is not appropriate.

Prior conservative management. ChondroFiller injection is a restorative step, not a first resort. Physiotherapy, activity modification, and injection therapies such as corticosteroid or hyaluronic acid should have been tried and found insufficient before a regenerative scaffold is considered.

Age. There is no upper age limit. This matters practically for patients in their 50s or 60s who have been told cartilage repair is not an option: that restriction belongs to cell-based procedures such as ACI or MACI, which require harvesting and culturing the patient's own chondrocytes and carry age or tissue-quality thresholds. ChondroFiller injection works by recruiting the patient's existing progenitor cells via the scaffold, so no such threshold applies.

One product-specific contraindication to declare at assessment is allergy to murine-derived proteins. The scaffold is produced from mouse-derived collagen; most candidates will have no such allergy, but it must be confirmed before treatment proceeds.

How the ChondroFiller collagen scaffold repairs the defect

The mechanism is sequential, and each stage depends on the one before it.

ChondroFiller is an acellular solution of purified Type I collagen derived from murine tissue. It contains no cells of any kind — no harvested chondrocytes, no stem cells, no donor tissue. What arrives at the defect is a structural material whose sole job is to create conditions in which the patient's own biology can do the repair work.

The phase-change is the first critical event. At body temperature and in contact with the physiological environment inside the joint, the liquid collagen transitions to a stable hydrogel within 3–5 minutes. This is why accurate placement under real-time ultrasound guidance is not simply a procedural preference — it is a biological requirement. If the material disperses into the surrounding synovial fluid before it sets, the scaffold forms in the wrong place and the subsequent biological chain cannot occur at the lesion site.

Once the gel has formed inside the defect, it acts as a chemotactic matrix — releasing signals that draw progenitor cells from the adjacent synovium and the subchondral bone beneath the lesion. These are the patient's own repair cells; they migrate into the scaffold, settle within its fibrous structure, and begin producing cartilage matrix. This process — acellular matrix-induced chondrogenesis — is the mechanism by which new tissue gradually forms.

The scaffold itself is temporary. Over months to years it biodegrades as the maturing cartilage tissue consolidates in its place, leaving no permanent implant behind.

The four stages — flow, gel, recruit, build — are interdependent. This is also why NSAIDs are avoided in the recovery period: anti-inflammatory agents may blunt the progenitor-cell recruitment the scaffold depends on, interrupting the chain at its most biologically active stage. The approach is regenerative rather than transplant-based; the scaffold provides the architecture, and the patient provides the biology.

What the ultrasound-guided injection procedure involves

On the day of treatment, nothing about the setting resembles a surgical admission. The appointment takes approximately one hour in a clinic room — no operating theatre, no general anaesthetic, no incision, and no overnight stay.

After imaging review and defect mapping from the pre-procedural MRI, the clinician positions an ultrasound probe over the shoulder to establish live visualisation of the glenohumeral joint. Intravenous antibiotic cover is administered before the needle is introduced. The collagen solution is then delivered percutaneously under continuous real-time guidance, placed directly into the centre of the focal defect. As described in the preceding section, accurate placement is a biological requirement: the scaffold must gel in situ within the lesion rather than dispersing into the surrounding joint space.

Post-procedure instructions carry a small number of specific restrictions. NSAIDs — ibuprofen, naproxen, and diclofenac — must be avoided; paracetamol is the preferred analgesic. The reason follows from the mechanism: anti-inflammatory agents may blunt the progenitor-cell recruitment the scaffold depends on, and self-medicating with a standard over-the-counter painkiller could interrupt the repair chain at its most biologically active stage. Separately, saunas, hot showers, and activities producing significant sweating are restricted for the first 72 hours, and localised shockwave or laser therapy on the treated shoulder should be deferred for approximately one week.

Movement is reintroduced progressively. Gentle range-of-motion work begins early, while high-load and high-impact shoulder activity waits until the scaffold integration period — typically several weeks — has passed, after which loading is incrementally restored as the maturing tissue consolidates.

The entire treatment is completed in a single visit: there is no biopsy appointment, no laboratory waiting period, and no separate implantation surgery.

What outcomes patients can realistically expect

The numbers that exist come largely from knee and hip series. In knee studies anchored to the manufacturer's April 2025 Clinical Evaluation Report (CER v09), IKDC scores improve by approximately 30 points over one year — a clinically meaningful gain on a 100-point scale that captures pain, function, and activity level. Hip series show comparable improvements in the modified Harris Hip Score (mHHS). Across joints, MOCART scores — MRI-based assessments of cartilage fill quality — sit between 70 and 87, providing objective imaging evidence that the scaffold integrates and new tissue forms within the treated defect.

For the glenohumeral joint specifically, shoulder-specific quantitative outcome data have not yet been separately published in the peer-reviewed literature. The shoulder indication is supported by a well-characterised mechanism and the multi-joint clinical track record described above, rather than a dedicated glenohumeral trial.

The most directly relevant surgical benchmark comes from two long-term glenohumeral series — Hünnebeck (2017) and Millett (2009) — which document functional improvement after glenohumeral microfracture in the short term, followed by declining results as fibrocartilage gradually breaks down and the subchondral bone plate sustains damage from the procedure itself. The ChondroFiller injection pathway is designed to avoid those limitations: the scaffold recruits progenitor cells without disrupting subchondral bone, and the tissue that forms follows a hyaline-like rather than fibrocartilage pathway.

Benefit duration across the multi-joint evidence base is cited as approximately three to five years, though shoulder-specific cohort data confirming that figure in the glenohumeral joint are not yet available.

For patients whose presentation is more complex — a larger defect, early background OA, or a prior failed microfracture — a structured longitudinal programme is a more realistic frame than a single-episode treatment. In practice, this might mean bi-annual ChondroFiller top-up injections combined with yearly MRI review, allowing the treating clinician to monitor cartilage quality, time any further intervention, and keep joint replacement further on the horizon rather than closer.

Assessment and treatment at the London Cartilage Clinic

Access to ChondroFiller injection in the UK is currently available on a self-funded private basis only — it is not commissioned by the NHS and is not covered by major private medical insurers including Bupa and AXA. Costs range from approximately £3,000 for a single-box injection to around £8,000 depending on defect size and volume, with the appointment fee including consultation, ultrasound, intravenous antibiotic cover, and a six-week follow-up.

The London Cartilage Clinic on Harley Street is the UK certified delivery centre for the product. Assessment there involves review of existing MRI findings, defect characterisation, and a structured discussion of the full shoulder-preservation pathway — ChondroFiller injection is considered where the anatomy supports it, not as a default. Patients can bring existing MRI scans; where recent imaging is unavailable, this can be arranged as part of the workup.

Technique precision at the injection stage is a meaningful variable in outcomes — accurate placement within the defect boundary determines whether gelation occurs in situ or the scaffold disperses. Professor Paul Y. F. Lee, who leads the service, was the first clinician in the UK to deliver ChondroFiller via the injection-only route.

Liquid Cartilage™ is delivered in the UK at the London Cartilage Clinic on Harley Street. Appointments and further information are available at londoncartilage.com.